Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer.

BACKGROUND & AIMS By using methylation-sensitive representational difference analysis, we identified protocadherin 10 (PCDH10), a gene that encodes a protocadherin and is silenced in a tumor-specific manner. We analyzed its epigenetic inactivation, biological effects, and prognostic significance in gastric cancer. METHODS Methylation status was evaluated by combined bisulfite restriction analysis and bisulfite sequencing. The effects of PCDH10 re-expression were determined in growth, apoptosis, proliferation, and invasion assays. PCDH10 target genes were identified by complementary DNA microarray analysis. RESULTS PCDH10 was silenced or down-regulated in 94% (16 of 17) of gastric cancer cell lines; expression levels were restored by exposure to demethylating agents. Re-expression of PCDH10 in MKN45 gastric cancer cells reduced colony formation in vitro and tumor growth in mice; it also inhibited cell proliferation (P < .01), induced cell apoptosis (P < .001), and repressed cell invasion (P < .05), up-regulating the pro-apoptosis genes Fas, Caspase 8, Jun, and CDKN1A; the antiproliferation gene FGFR; and the anti-invasion gene HTATIP2. PCDH10 methylation was detected in 82% (85 of 104) of gastric tumors compared with 37% (38 of 104) of paired nontumor tissues (P < .0001). In the latter, PCDH10 methylation was higher in precancerous lesions (27 of 45; 60%) than in chronic gastritis samples (11 of 59; 19%) (P < .0001). After a median follow-up period of 16.8 months, multivariate analysis revealed that patients with PCDH10 methylation in adjacent nontumor areas had a significant decrease in overall survival. Kaplan-Meier survival curves showed that PCDH10 methylation was associated significantly with shortened survival in stage I-III gastric cancer patients. CONCLUSIONS PCDH10 is a gastric tumor suppressor; its methylation at early stages of gastric carcinogenesis is an independent prognostic factor.

[1]  Jian Zhao,et al.  TIP30 induces apoptosis under oxidative stress through stabilization of p53 messenger RNA in human hepatocellular carcinoma. , 2008, Cancer research.

[2]  M. Pear,et al.  Three-dimensional model of human TIP30, a coactivator for HIV-1 Tat-activated transcription, and CC3, a protein associated with metastasis suppression , 2000, Cellular and Molecular Life Sciences CMLS.

[3]  S. Nishizuka,et al.  Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. , 2002, The American journal of pathology.

[4]  Jun Yu,et al.  Inactivation of helicase‐like transcription factor by promoter hypermethylation in human gastric cancer , 2003, Molecular carcinogenesis.

[5]  H. Maruyama,et al.  Functional , 2020, Congress of Neurological Surgeons Essent.

[6]  B. Kaina,et al.  DNA damage-induced cell death by apoptosis. , 2006, Trends in molecular medicine.

[7]  Y. Kanno,et al.  A Fas-Associated Death Domain Protein/Caspase-8-Signaling Axis Promotes S-Phase Entry and Maintains S6 Kinase Activity in T Cells Responding to IL-21 , 2007, The Journal of Immunology.

[8]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[9]  R. Watson,et al.  Altered DNA methylation: a secondary mechanism involved in carcinogenesis. , 2002, Annual review of pharmacology and toxicology.

[10]  J. Issa.  Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  S. Hirohashi,et al.  Frequent silencing of the candidate tumor suppressor PCDH20 by epigenetic mechanism in non-small-cell lung cancers. , 2006, Cancer research.

[12]  P. Malfertheiner,et al.  Absence of cyclin D2 expression is associated with promoter hypermethylation in gastric cancer , 2003, British Journal of Cancer.

[13]  Hwoong-Yong Jung,et al.  Profile of Aberrant CpG Island Methylation Along the Multistep Pathway of Gastric Carcinogenesis , 2003, Laboratory Investigation.

[14]  T. Marafioti,et al.  Frequent epigenetic silencing of protocadherin 10 by methylation in multiple haematologic malignancies , 2007, British journal of haematology.

[15]  Yung-Hyun Choi,et al.  Induction of G2/M arrest and apoptosis by water extract of Strychni Semen in human gastric carcinoma AGS cells , 2008, Phytotherapy research : PTR.

[16]  George A. Calin,et al.  Frequent Aberrant Methylation of the CDH4 Gene Promoter in Human Colorectal and Gastric Cancer , 2004, Cancer Research.

[17]  W. Leung,et al.  Effects of Helicobacter pylori Eradication on Methylation Status of E-Cadherin Gene in Noncancerous Stomach , 2006, Clinical Cancer Research.

[18]  Jun Yu,et al.  Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer , 2007, British Journal of Cancer.

[19]  Jian Zhao,et al.  TIP 30 Induces Apoptosis under Oxidative Stress through Stabilization of p 53 Messenger RNA in Human Hepatocellular Carcinoma , 2008 .

[20]  Y. Kodera,et al.  Methylation pattern of CDH13 gene in digestive tract cancers , 2004, British Journal of Cancer.

[21]  T. Putti,et al.  Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation , 2006, Oncogene.

[22]  H. Putter,et al.  Epigenetic silencing of cyclooxygenase-2 affects clinical outcome in gastric cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Hyeon Joo Lee,et al.  Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. , 2003, The American journal of pathology.

[24]  D. Hoon,et al.  Epigenetic Inactivation of ID4 in Colorectal Carcinomas Correlates with Poor Differentiation and Unfavorable Prognosis , 2004, Clinical Cancer Research.

[25]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[26]  Jun Yu,et al.  Promoter hypermethylation of tumor‐related genes in gastric intestinal metaplasia of patients with and without gastric cancer , 2002, International journal of cancer.

[27]  K. Miyazaki,et al.  Helicobacter pylori infection is an independent risk factor for Runx3 methylation in gastric cancer. , 2008, Oncology reports.

[28]  N. Saijo,et al.  AZD2171 Shows Potent Antitumor Activity Against Gastric Cancer Over-Expressing Fibroblast Growth Factor Receptor 2/Keratinocyte Growth Factor Receptor , 2007, Clinical Cancer Research.

[29]  B. Iacopetta,et al.  CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  Yan Zhao,et al.  c-Jun N-terminal kinase is required for vitamin E succinate-induced apoptosis in human gastric cancer cells. , 2004, World journal of gastroenterology.

[31]  S. Hirohashi,et al.  Alterations of DNA methylation associated with abnormalities of DNA methyltransferases in human cancers during transition from a precancerous to a malignant state. , 2007, Carcinogenesis.

[32]  Jun Yu,et al.  Promoter hypermethylation of cyclooxygenase-2 in gastric carcinoma. , 2003, International journal of oncology.

[33]  Jun Yu,et al.  Concurrent hypermethylation of multiple tumor‐related genes in gastric carcinoma and adjacent normal tissues , 2001, Cancer.